IL-21 is expressed in Hodgkin lymphoma and activates STAT5: Evidence that activated STAT5 is required for Hodgkin lymphomagenesis

Blood

Volumn 111, Issue 9, 2008, Pages 4706-4715

  Scheeren, Ferenc A ^a   Diehl, Sean A ^a   Smit, Laura A ^a   Beaumont, Tim ^b   Naspetti, Marianne ^a   Bende, Richard J ^a   Blom, Bianca ^a   Karube, Kennosuke ^c   Ohshima, Koichi ^c   Van Noesel, Carel J M ^a   Spits, Hergen ^a,d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b AIMM Therapeutics   (Netherlands)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAKPOINT CLUSTER REGION PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; STAT3 PROTEIN; STAT5 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E47; UNCLASSIFIED DRUG; INTERLEUKIN DERIVATIVE; TUMOR PROTEIN;

ARTICLE; B LYMPHOCYTE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; METABOLISM; PATHOLOGY; PHYSIOLOGY;

B-LYMPHOCYTES; HODGKIN DISEASE; HUMANS; INTERLEUKINS; NEOPLASM PROTEINS; NF-KAPPA B; RECEPTORS, INTERLEUKIN-21; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR;

EID: 47149098995     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-08-105643     Document Type: Article

References (50)

1. Kuppers R, Rajewsky K. The origin of Hodgkin and Reed/Stern berg cells in Hodgkin's disease. Annu Rev Immunol. 1998;16:471-493.
2. Thomas RK, Re D, Wolf J, Diehl V. Part I: Hodgkin's lymphoma: molecular biology of Hodgkin and Reed-Sternberg cells. Lancet Oncol. 2004;5:11-18.
3. Kuppers R, Rajewsky K, Zhao M, et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A. 1994;91:10962-10966.
4. Schwering I, Brauninger A, Klein U, et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2003;101:1505-1512.
5. Kanzler H. Kuppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med. 1996; 184:1495-1505.
6. Hertel CB, Zhou XG, Hamilton-Dutoit SJ, Junker S. Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin/Reed-Sternberg cells of classical Hodgkin lymphoma. Oncogene. 2002;21:4908-4920.
7. Jundt F. Kley K. Anagnostopoulos I. et al. Loss of PU. 1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed Sternberg cells of classical Hodgkin disease. Blood. 2002;99:3060-3062.
8. Stein H, Marafioti T Foss HD, et al. Down-regulation of BOB. 1/OBF 1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood. 2001;97:496-501.
9. Ushmorov A, Ritz O, Hummel M, et al. Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression. Blood. 2004;104:3326-3334.
10. Bain G, Gruenwald S, Murre C. E2A and E2-2 are subunits of B-cell-specific E2-box DNA-binding proteins. Mol Cell Biol. 1993;13:3522-3529.
11. Mathas S, Janz M, Hummel F, et al. Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol. 2006;7:207-215.
12. Murre C. Regulation and function of the E2A proteins in B cell development. Adv Exp Med Biol. 2007;596:1-7.
13. Hsu SM, Jaffe ES. Leu MI and peanut agglutinin stain the neoplastic cells of Hodgkin's disease. Am J Clin Pathol. 1984;82:29-32.
14. Gruss HJ, DaSilva N, Hu ZB, Uphoff CC, Goodwin RG, Drexler HG. Expression and regulation of CD30 ligand and CD30 in human leukemialymphoma cell lines. Leukemia. 1994;8:2083-2094.
15. Atayar C, Poppema S, Blokzij IT, Harms G, Boot M. van den Berg A. Expression of the T-cell transcription factors. GATA-3 and T-bet. in the neoplastic cells of Hodgkin lymphomas. Am J Pathol. 2005;166:127-134.
16. Bargou RC, Leng C, Krappmann D. et al. Highlevel nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood. 1996;87:4340-4347.
17. Bargou RC, Emmerich F, Krappmann D. et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest. 1997;100:2961-2969.
18. Kuppers R. Molecular biology of Hodgkin's lymphoma. Adv Cancer Res. 2002;84:277-312.
19. Sasaki Y, Schmidt-Supprian M, Derudder E, Rajewsky K. Role of NFkappaB signaling in normal and malignant B cell development. Adv Exp Med Biol. 2007;596:149-154.
20. Kube D, Holtick U, Vockerodt M, et al. STAT3 is constitutively activated in Hodgkin cell lines. Blood. 2001;98:762-770.
21. Hinz M, Lemke P. Anagnostopoulos I, et al. Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med. 2002;196:605-617.
22. Skinnider BF, Kapp U, Mak TW. The role of interleukin 13 in classical Hodgkin lymphoma. Leuk Lymphoma. 2002;43:1203-1210.
23. Shimoda K, van Deursen J, Sangster MY, et al. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature. 1996;380:630-633.
24. Reljic R, Wagner SD, Peakman LJ, Fearon DT. Suppression of signal transducer and activator of transcription 3-dependent B lymphocyte terminal differentiation by BCL-6. J Exp Med. 2000;192:1841-1848.
25. Scheeren FA, Naspetti M, Diehl S, et al. STAT5 regulates the self-renewal capacity and differentiation of human memory B cells and controls Bcl-6 expression. Nat Immunol. 2005;6:303-313.
26. Fornek JL, Tygrett LT, Waldschmidt TJ, Poli V, Rickert RC, Kansas GS. Critical role for Stat3 in T-dependent terminal differentiation of IgG B cells. Blood. 2006;107:1085-1091.
27. Diehl SA, Schmidlin H, Nagasawa M, et al. STAT3-mediated upregulation of BLIMP1 is coordinated with BCL6 downregulation to control human plasma cell differentiation. J Immunol. 2008; 180:4805-4815.
28. Ozaki K, Kikly K, Michalovich D. Young PR, Leonard WJ. Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc Natl Acad Sci U S A. 2000;97:11439-11444.
29. Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature. 2000;408:57-63.
30. Asao H, Okuyama C, Kumaki S, et al. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol. 2001;167:1-5.
31. Jaffa ESVJ. World Health Organization classification of tumours. Lyon, France: IARC Press; 2001.
32. Onishi M, Nosaka T. Misawa K, et al. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol Cell Biol. 1998;18:3871-3879.
33. Van Der Loos C. Afocus on fixation. Biotechnic Histochem. 2007;82:141-154.
34. Karube K, Ohshima K, Suzumiya J, Kawano R, Kikuchi M, Harada M. Gene expression profile of cytokines and chemokines in microdissected primary Hodgkin and Reed-Sternberg (HRS) cells: high expression of interleukin-11 receptor alpha. Ann Oncol. 2006;17:110-116.
35. Kapp U, Yeh WC, Patterson B. et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med. 1999;189:1939-1946.
36. Kuppers R, Klein U, Schwering I, et al. Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J Clin Invest. 2003:111:529-537.
37. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257-2317.
38. Drexler HG. Recent results on the biology of Hodgkin and Reed-Sternberg cells, I: biopsy material. Leuk Lymphoma. 1992;8:283-313.
39. Berberich I, Shu GL, Clark EA. Cross-linking CD40 on B cells rapidly activates nuclear factorkappa B. J Immunol. 1994;153:4357-4366.
40. Haskill S, Beg AA, Tompkins SM, et al. Characterization of an immediate-early gene induced in adherent monocytes that encodes I kappa B-like activity. Cell. 1991;65:1281-1289.
41. Nakamura T, Ouchida R, Kodama T, et al. Cytokine receptor common beta subunit-mediated STAT5 activation confers NF-kappa B activation in murine proB cell line Ba/F3 cells. J Biol Chem. 2002;277:6254-6265.
42. Schepers H, Eggen BJ, Schuringa JJ, Vellenga E. Constitutive activation of NF-kappa B is not sufficient to disturb normal steady-state hematopoiesis. Haematologica. 2006;91:1710-1711.
43. Rolling C, Treton D, Pellegrini S, Galanaud P, Richard Y. IL4 and IL13 receptors share the gamma c chain and activate STAT6, STATS and STAT5 proteins in normal human Bcells. FEBS Lett. 1996;393:53-56.
44. Nosaka T, Kitamura T. Pim-1 expression is sufficient to induce cytokine independence in murine hematopoietic cells, but is dispensable for BCRABL-mediated transformation. Exp Hematol. 2002;30:697-702.
45. Nosaka T, Kawashima T, Misawa K, Ikuta K, Mui AL, Kitamura T STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. Embo J. 1999;18:4754-4765.
46. Jucker M, Schaadt M, Diehl V, Poppema S, Jones D, Tesch H. Heterogeneous expression of protooncogenes in Hodgkin's disease derived cell lines. Hematol Oncol. 1990;8:191-204.
47. Yamada K, Ariyoshi K, Onishi M, et al. Constitutively active STAT5A and STAT5B in vitro and in vivo: mutation of STAT5 is not a frequent cause of leukemogenesis. Int J Hematol. 2000;71:46-54.
48. Weniger MA, Melzner I, Menz CK, et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene. 2006;25:2679-2684.
49. Endo TA, Masuhara M, Yokouchi M, et al. Anew protein containing an SH2 domain that inhibits JAK kinases. Nature. 1997;387:921-924.
50. Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signaling. Stem Cells. 2001;19:378-387.